Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.34 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18477159 | 0.90 | HSP90AA1 (0.33) | HSP90AA1CTSLHKDC1 | |
| SCHEMBL18477151 | 0.89 | REN (0.34) | HSP90AA1RENCTSL | |
| SCHEMBL18477150 | 0.88 | REN (0.35) | HSP90AA1RENCTSLPRKCQ | |
| SCHEMBL18477166 | 0.87 | HSP90AA1 (0.38) | HSP90AA1CTSLHKDC1 | |
| SCHEMBL18476896 | 0.84 | HSP90AA1 (0.33) | HSP90AA1RENHRH4PRKCQ | |
| SCHEMBL20414196 | 0.83 | ATR (0.30) | CTSL | |
| SCHEMBL18477858 | 0.83 | HSP90AA1 (0.33) | HSP90AA1RENCTSLHRH4PRKCQ | |
| SCHEMBL18479556 | 0.83 | HRH4 (0.32) | CTSLHRH4 | |
| SCHEMBL18477152 | 0.83 | HSP90AA1 (0.39) | HSP90AA1CTSLHRH4HKDC1 | |
| SCHEMBL18477181 | 0.83 | REN (0.30) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | NANTBIO, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC | 2018-07-26 | — | — | US | disclosed |
| WO-2017024315-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392397-B2 | Heterocyclic thiosemicarbazone derivatives and their therapeutical applications | TPMT, MKI67, TST | HSP90AA1 158/4885REN 691/4885CTSL 2976/4885 |
| US-20180208603-A1 | HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | TPMT, MKI67, TST | HSP90AA1 158/4885REN 691/4885CTSL 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.